aTYR PHARMA INC — Operating Income by Fiscal Year
13 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/4d43f5b7-ddba-4148-a256-1b01cd3424c4/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-77.6M | 2025-01-01 – 2025-12-31 | evidence 0001339970-26-000008 |
| FY 2024 | $-67.9M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-038888 |
| FY 2023 | $-54.9M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-031584 |
| FY 2022 | $-46.4M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-007873 |
| FY 2021 | $-34.0M | 2021-01-01 – 2021-12-31 | evidence 0001564590-22-010441 |
| FY 2020 | $-15.9M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-014940 |
| FY 2019 | $-23.0M | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-013208 |
| FY 2018 | $-32.8M | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-009381 |
| FY 2017 | $-47.1M | 2017-01-01 – 2017-12-31 | evidence 0001564590-18-006333 |
| FY 2016 | $-57.9M | 2016-01-01 – 2016-12-31 | evidence 0001564590-17-004631 |
| FY 2015 | $-47.6M | 2015-01-01 – 2015-12-31 | evidence 0001564590-16-015652 |
| FY 2014 | $-23.6M | 2014-01-01 – 2014-12-31 | evidence 0001564590-16-015652 |
| FY 2013 | $-19.5M | 2013-01-01 – 2013-12-31 | evidence 0001564590-16-015652 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).